Host Defense Mechanisms Against Bacteria

Fetal and Neonatal Physiology: Third Edition

Volumn 2-2, Issue , 2003, Pages 1475-1486

  La Pine, Timothy R ^a   Hill, Harry R ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33846919811     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7216-9654-6.50154-5     Document Type: Chapter

References (252)

1. Baker CJ Group B streptococcal infections. Clin Perinatol 1997, 24:59. In Stoll BJ, Weisman LE (eds): Infections in Perinatology.
2. Stoll BJ The global impact of neonatal infection. Clin Perinatol 1997, 24:1. In Stoll BJ, Weisman LE (eds): Infections in Perinatology.
3. Hill HR Diagnosis and treatment of sepsis in the neonate. Septic Shock: Contemporary Topics in Infectious Diseases 1985, 219-232. Churchill Livingstone, New York. R.K. Root, M.A. Sand (Eds.).
4. Santos JI, Hill HR Bacterial infections in the neonate. Infections in Children 1982, 179-202. Harper and Row, Philadelphia. R.J. Wedgwood (Ed.).
5. Starr SE Antimicrobial therapy of bacterial sepsis in the newborn infant. J Pediatr 1985, 106:1043.
6. Hill HR Group B streptococcal infections. Sexually Transmitted Diseases 1984, 397-407. McGraw Hill, New York. K.K. Holmes (Ed.).
7. Stoll BJ, et al. Changes in pathogens causing early-onset sepsis in very-low-birth-weight infants. N Engl J Med 2002, 347:240.
8. Noel GJ, Edelson PJ Staphylococcus epidermidis bacteremia in neonates: further observations and the occurrence of focal infection. Peditatrics 1984, 74:832.
9. Simor AE, et al. Abortion and perinatal sepsis associated with Campylobacter infection. Rev Infect Dis 1986, 8:397.
10. Hoffman JA, et al. Phylogenetic perspectives in innate immunity. Science 1999, 284:1313.
11. Qureshi ST, et al. Comparative genomics and host resistance against infectious diseases. Emerg Infect Dis 1999, 5:36.
12. Boman HG Innate immunity and the normal microflora. Immunol Rev 2000, 173:5.
13. Schoen EJ, et al. Newborn circumcision decreases incidence and costs of urinary tract infections during the first year of life. Pediatrics 2000, 105:789.
14. Wiswell TE The prepuce, urinary tract infections, and the consequences. Comment Pediatr 2000, 105:860.
15. Wiswell TE, et al. Effect of circumcision status on periurethral bacterial flora during the first year of life. J Pediatr 1988, 113:442.
16. Glennon J, et al. Circumcision and periurethral carriage of Proteus mirabilis in boys. Arch Dis Child 1988, 63:556.
17. Fussell EN, et al. Adherence of bacteria to human foreskins. J Urol 1988, 140:997.
18. Nealon TJ, Mattingly SJ Role of cellular lipoteichoic acids in mediating adherence of serotype III strains of group B streptococci to human embryonic, fetal, and adult epithelial cells. Infect Immun 1984, 43:523.
19. Cox F, et al. Prevention of group B streptococcal colonization and bacteremia in neonatal mice with topical vaginal inhibitors. J Infect Dis 1993, 167:1118.
20. Miyazaki S, et al. Adherence of Streptococcus agalactiae to synchronously growing human cell monolayers without lipoteichoic acid and involvement. Infect Immun 1988, 56:505.
21. Tamura GS, et al. Adherence of group B streptococci to cultured epithelial cells: roles of environmental factors and bacterial surface components. Infect Immun 1994, 62:2450.
22. Rubens CE, et al. Respiratory epithelial cell invasion by group B streptococci. Infect Immun 1992, 60:5157.
23. Zhang P, et al. Innate immunity and pulmonary host defense. Immunol Rev 2000, 173:39.
24. Rose MC Mucins: structure, function, and role in pulmonary diseases. Am J Physiol 1992, 263:L413-L429.
25. Diamond G, et al. The innate immune responses of the respiratory epithelium. Immunol Rev 2000, 173:27.
26. Dohrman A, et al. Mucin gene (MUC 2 and MUC 5AC) upregulation by gram-positive and gram-negative bacteria. Biochim Biophys Acta 1998, 1406:251.
27. Travis SM, et al. Activity of abundant antimicrobials of the human airway. Am J Respir Cell Mol Biol 1999, 20:872.
28. Harbitz O, et al. Lysozyme and lactoferrin in sputum from patients with chronic obstructive lung disease. Eur J Respir Dis 1984, 65:512.
29. McCray PB, et al. Efficient killing of inhaled bacterial in DeltaF508 mice: role of airway surface liquid composition. Am J Physiol 1999, 277:L183.
30. Srivastava MD, Walker WA The development of the mucosal immune system in the sick neonate. Neonatal Hematology and Immunology III 1997, 115-120. Elsevier Science, New York. J.A. Bellanti (Ed.).
31. Siafakas C, et al. Breast milk cells and their interaction with intestinal mucosa. Neonatal Hematology and Immunology III 1997, 121-126. Elsevier Science, New York. J.A. Bellanti (Ed.).
32. Kelemen E, et al. Atlas of Human Hemopoietic Development 1979, Springer-Verlag, New York.
33. Kelemen E, Janossa M Macrophages are the first differentiated blood cells formed in human embryonic liver. Exp Hematol 1980, 8:996.
34. Slayton WB, et al. Hematopoiesis in the liver and marrow of human fetuses at 5 to 16 weeks' postconception: quantitative assessment of macrophage and neutrophil populations. Pediatr Res 1998, 43:774.
35. Yang KD, et al. Phagocytic system. Primary Immunodeficiency Diseases. A Molecular and Genetic Approach 1999, 82-96. Oxford University Press, New York. H.D. Ochs (Ed.).
36. Hill HR Biochemical, structural, and functional abnormalities of polymorphonuclear leukocytes in the neonate. Pediatr Research 1987, 22:375.
37. Schibler K Leukocyte development and disorders during the neonatal period. Hematologic Problems of the Neonate 2000, 311-342. WB Saunders, Philadelphia. R. Christensen (Ed.).
38. Bohnsack JF CD11/CD18-independent neutrophil adherence to laminin is mediated by integrin VLA-6. Blood 1992, 79:1545.
39. Bohnsack JF, Zhou X Divalent cation substitution reveals CD18- and very late antigen-dependent pathways that mediate human neutrophil adherence to fibronectin. J Immunol 1992, 149:1340.
40. Gresham HD, et al. Pertussis toxin and cholera toxin modulation of human neutrophil Fc-receptor-mediated phagocytosis. J Cell Biol 1986, 103:215A.
41. Wright WC, et al. Decreased bactericidal activity of leukocytes of stressed newborn infants. Pediatrics 1975, 56:579.
42. Shigeoka AO, et al. Functional analysis of neutrophil granulocytes from healthy, infected, and stressed neonates. J Pediatr 1979, 95:454.
43. Borregaard N, Cowland JB Granules of the human neutrophilic polymorphonuclear leukocyte. Blood 1997, 89:3503.
44. Xing X, et al. Cytokine expression by neutrophils and macrophages in vivo: endotoxin induces tumor necrosis factorα, macrophage inflammatory protein-2, interleukin-1β, and interleukin-6 but not RANTES or transforming growth factorβ1 mRNA expression in acute lung inflammation. Am J Respir Cell Mol Biol 1994, 10:148.
45. Marodi L, et al. Chemotactic and random movement of human newborn monocytes. Eur J Pediatr 1980, 135:73.
46. Klein RB, et al. Decreased mononuclear and polymorphonuclear chemotaxis in human newborns, infants, and young children. Pediatrics 1977, 60:467.
47. Roth P, Polin RA Adherence of human newborn infants' monocytes to matrix-bound fibronectin. J Pediatr 1992, 121:285.
48. Nathan CF, Tsunawaki S Secretion of toxic oxygen products by macrophages: regulatory cytokines and their effects on the oxidase. Ciba Found Symp 1986, 118:211.
49. Reiss M, Roos D Differences in oxygen metabolism of phagocytosing monocytes and neutrophils. J Clin Invest 1978, 61:480.
50. Speer CP, Johnston RB Phagocyte function. Neonatal Infections: Nutritional and Immunological Interactions 1984, 21-36. Grune & Stratton, Orlando, FL. P.L. Ogra (Ed.).
51. D'Ambola JB, et al. Human and rabbit newborn lung macrophages have reduced anti-Candida activity. Pediatr Res 1988, 68:285.
52. Nathan CF Secretory products of macrophages. J Clin Invest 1987, 1987:319.
53. Bessler H, et al. Production of interleukin-1 by mononuclear cells of newborns and their mothers. Clin Exp Immunol 1987, 68:655.
54. Wilson CB Immunologic basis for increased susceptibility of the neonate to infection. J Pediatr 1986, 108:1.
55. Weatherstone KB, Rich EA Tumor necrosis factor/cachectin and interleukin-1 expression in cord blood monocytes from term and preterm neonates. Pediatr Res 1989, 25:342.
56. Bryson YJ, et al. Deficiency of immune interferon production by leukocytes of normal newborns. Cell Immunol 1980, 55:191.
57. 4 and interleukin-8 from human monocytes: neonates exhibit a diminished response. J Infect Dis 1995, 712:420.
58. Schibler KR, et al. Diminished transcription of interleukin-8 by monocytes from preterm neonates. J Leukoc Biol 1993, 53:399.
59. Le T, et al. Regulation of interleukin-10 gene expression: possible mechanisms accounting for its up-regulation and for maturational differences in its expression by blood mononuclear cells. Blood 1997, 89:4112.
60. Schibler KR, et al. Production of granulocyte colony-stimulating factor by monocytes from preterm and term neonates. Blood 1993, 82:2478.
61. Van Furth R Cellular biology of pulmonary macrophages. Int Arch Allergy Appl Immunol 1985, 76:21.
62. Sorokin SP, et al. CFU-rAM, the origin of lung macrophages, and the macrophage lineage. Am J Physiol 1992, 263:L299.
63. Naito M, et al. Development, differentiations, and maturation of macrophages in the fetal mouse liver. J Leukoc Biol 1990, 48:27.
64. Standiford TJ, et al. Expression and regulation of chemokines in bacterial pneumonia. J Leukoc Biol 1996, 59:24.
65. Sibille Y, Reynolds HY Macrophages and polymorphonuclear neutrophils in lung defense and injury. Am Rev Respir Dis 1990, 141:471.
66. Hart DN Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997, 90:3245.
67. Steinman RM, Cohn ZA Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, and tissue distribution. J Exp Med 1993, 137:1142.
68. Mekori YA, Metcalfe DD Mast cells in innate immunity. Immunol Rev 2000, 173:131.
69. Sher A Complement-dependent adherence of mast cells to schistosomula. Nature 1976, 263:334.
70. Sher A, et al. Complement receptors promote the phagocytosis of bacteria by rat peritoneal mast cells. Lab Invest 1979, 41:490.
71. Arock M, et al. Phagocytic and tumor necrosis factorα response of human mast cells following exposure to gram-negative and gram-positive bacteria. Infect Immun 1998, 66:6030.
72. Malaviya R, et al. Mast cell phagocytosis of FimH-expressing enterobacteria. J Immunol 1994, 152:1907.
73. Bidri M, et al. Evidence for direct interaction between mast cells and Leishmania parasites. Parasite Immunol 1997, 19:475.
74. Malaviya R, et al. The mast cell tumor necrosis factorα response to FimH-expressing E. coli is mediated by the glycosylphosphatidylinositol-anchored molecule CD48. Proc Natl Acad Sci U S A 1999, 96:8110.
75. Malaviya R, et al. Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-alpha. Nature 1996, 381:77.
76. Echtenacher B, et al. Critical protective role of mast cells in a model of acute septic peritonitis. Nature 1996, 381:75.
77. Gaboury JP, et al. Mechanisms underlying acute mast cell-induced leukocyte rolling and adhesion in vivo. J Immunol 1995, 154:804.
78. Abraham SN, Arock M Mast cell and basophils in innate immunity. Semin Immunol 1998, 10:373.
79. Mecheri S, David B Unravelling the mast cell dilemma: culprit or victim of its generosity?. Immunol Today 1997, 18:212.
80. Metcalfe DD, et al. Mast cells. Physiol Rev 1997, 77:1033.
81. Born W, et al. Immunoregulatory functions of γδ T cells. Adv Immunol 1999, 71:77.
82. Abbas AK, et al. Innate immunity. Cellular and Molecular Immunology 2000, 270-290. WB Saunders, Philadelphia. 4th ed. A.K. Abbas (Ed.).
83. Munk ME, et al. In vitro activation of human γδ T cells by bacteria: evidence for specific interleukin secretion and target cell lysis. Curr Top Microbiol Immunol 1991, 173:159.
84. Kabelitz D, et al. A large fraction of human peripheral blood γδ T cells is activated by Mycobacterium tuberculosis but not by its 65-kDa heat shock protein. J Exp Med 1990, 171:667.
85. Carding SR, Egan PJ The importance of γδ T cells in the resolution of pathogen-induced inflammatory immune responses. Immunol Rev 2000, 173:98.
86. Hardy RR, Hayakawa K CD5 B cells, a fetal B cell lineage. Adv Immunol 1994, 55:297.
87. Gommerman JL, Carroll MC Negative selection of B lymphocytes: a novel role for innate immunity. Immunol Rev 2000, 173:120.
88. Boyden SV Natural antibodies and the immune response. Adv Immunol 1966, 5:1.
89. Avrameas S, Ternynck T The natural autoantibodies system: between hypotheses and facts. Mol Immunol 1993, 30:1133.
90. Ochsenbein AF, et al. Control of early viral and bacterial distribution and disease by natural antibodies. Science 1999, 286:2156.
91. h gene segments in pre-B-cell lines. Nature 1984, 311:727.
92. Feeney AJ Lack of N regions in fetal and neonatal mouse immunoglobulin V-D-J junctional sequences. J Exp Med 1990, 172:1377.
93. Boes M, et al. A critical role of natural immunoglobulin M in immediate defense against systemic bacterial infection. J Exp Med 1998, 188:2381.
94. Mirilas P, et al. Natural antibodies in childhood: development, individual stability, and injury effect indicate a contribution to immune memory. J Clin Immunol 1999, 19:109.
95. La Pine TR, Hill HR: Complement disorders. In Osborn L, et al (eds): Comprehensive Pediatrics. St. Louis, Harcourt Health Sciences (in press).
96. Johnston RB The complement system in host defense and inflammation: the cutting edges of a double-edged sword. Pediatr Infect Dis J 1993, 12:933.
97. Schweinle JE, et al. Human mannose-binding protein activates the alternative complement pathway and enhances serum bactericidal activity on a mannose-rich isolate of Salmonella. J Clin Invest 1989, 84:1821.
98. Figueroa JE, Densen P Infectious diseases associated with complement deficiencies. Clin Microbiol Rev 1991, 4:359.
99. Hill HR, et al. Evaluation of nonspecific (alternative pathway) opsonic activity by neutrophil chemiluminescence. Int Arch Allergy Appl Immunol 1977, 53:490.
100. Lassiter HA, et al. Complement factor 9 deficiency in serum of human neonates. J Infect Dis 1992, 166:53.
101. Yang KD, et al. Fibronectin in host defense: implications in the diagnosis, prophylaxis and therapy of infectious diseases. Pediatr Infect Dis J 1993, 12:234.
102. Proctor RA, et al. Fibronectin mediates attachment of Staphylococcus aureus to human neutrophils. Blood 1982, 59:681.
103. Simpson WA, et al. Fibronectin-mediated binding of group A streptococci to human polymorphonuclear leukocytes. Infect Immun 1982, 37:805-810. 805.
104. Yang KD, et al. Effects of fibronectin on the interaction of polymorphonuclear leukocytes with unopsonized and antibody-opsonized bacteria. J Infect Dis 1988, 158:823.
105. Proctor RA Fibronectin: an enhancer of phagocyte function. Rev Infect Dis 1987, 9:S412.
106. Hill HR, et al. Mechanism of fibronectin enhancement of group B streptococcal phagocytosis by human neutrophils and culture-derived macrophages. Infect Immun 1993, 61:2334.
107. Jacobs RF, et al. Phagocytosis of type III group B streptococci by neonatal monocytes: enhancement by fibronectin and gammaglobulin. J Infect Dis 1985, 152:695.
108. Yang KD, et al. Effects of fibronectin on actin organization and respiratory burst activity in neutrophils, monocytes, and macrophages. J Cell Physiol 1994, 158:347.
109. Peat EB, et al. Effects of fibronectin and group B streptococci on tumour necrosis factorαproduction by human culture-derived macrophages. Immunology 1995, 84:440.
110. Hill HR, et al. Fibronectin deficiency: a correctable defect in the neonate's host defense mechanism. Pediatr Res 1983, 17:25A.
111. Barnard DR, Arthur MM Fibronectin (cold insoluble globulin) in the neonate. J Pediatr 1983, 102:453.
112. Akiyama SK, Yamada KM Fibronectin in disease. Connective Tissue Diseases 1983, 55-96. Williams & Wilkins, Baltimore. B. Wagner, N. Kaufman (Eds.).
113. 2 surface-binding glycoprotein deficiency in septic surgical and trauma patients. Science 1978, 201:622.
114. Lanser ME, et al. Opsonic glycoprotein (plasma fibronectin) levels after burn injury. Relationship to extent of burn and development of sepsis. Ann Surg 1980, 192:776.
115. Yoder MC, et al. Plasma fibronectin in healthy newborn infants, respiratory distress syndrome and perinatal asphyxia. J Pediatr 1983, 102:777.
116. Ganrot PO Variation of the concentration of some plasma proteins in normal adults, in pregnant women and in newborns. Scand J Clin Lab Invest 1972, 124:83.
117. Gerdes JS, et al. Decreased plasma fibronectin in neonatal sepsis. Pediatrics 1983, 72:877.
118. Medzhitov R, Janeway C Innate immunity. N Engl J Med 2000, 343:338.
119. Lawson PR, Reid KBM The roles of surfactant proteins A and D innate immunity. Immunol Rev 2000, 173:66.
120. Feizi T Carbohydrate-mediated recognition systems in innate immunity. Immunol Rev 2000, 173:79.
121. Turner MW Mannose-binding lectin: the pluripotent molecule of the innate immune system. Immunol Today 1996, 17:532.
122. Epstein J, et al. The collectins in innate immunity. Curr Opin Immunol 1996, 8:29.
123. Super M, et al. Association of low levels of mannan-binding protein with a common defect of opsonization. Lancet 1989, 2:1236.
124. Sumiya M, et al. Molecular basis of opsonic defect in immunodeficient children. Lancet 1991, 337:1569.
125. Crouch EC Modulation of host-bacterial interactions by collectins. Am J Respir Cell Mol Biol 1999, 21:558.
126. LaForce FM, et al. Inactivation of staphylococci by alveolar macrophages with preliminary observations on the importance of alveolar lining material. Am Rev Respir Dis 1973, 108:784.
127. Geertsma MF, et al. Binding of surfactant protein A to C1q receptors mediates phagocytosis of Staphylococcus aureus by monocytes. Am J Physiol 1994, 267:L578.
128. Stamme C, Wright JR Surfactant protein A enhances the binding and deacylation of E. coli LPS by alveolar macrophages. Am J Physiol 1999, 276:L540.
129. Zimmerman PE, et al. 120-kD surface glycoprotein of Pneumocystis carinii is a ligand for surfactant protein A. J Clin Invest 1992, 89:143.
130. Tino MJ, Wright JR Surfactant protein A stimulates phagocytosis of specific pulmonary pathogens by alveolar macrophages. Am J Physiol 1996, 270:L677.
131. McNeely TB, Coonrod JD Aggregation and opsonization of type A but not type B Hemophilus influenzae by surfactant protein A. Am J Respir Cell Mol Biol 1994, 11:114.
132. Schelenz S, et al. Binding of host collectins to the pathogenic yeast Cryptococcus neoformans: human surfactant protein D acts as an agglutinin for acapsular yeast cells. Infect Immun 1995, 63:3360.
133. Kabha K, et al. SP-A enhances phagocytosis of Klebsiella by interaction with capsular polysaccharides and alveolar macrophages. Am J Physiol 1997, 272:L344.
134. O'Riordan DM, et al. Surfactant protein D interacts with Pneumocystis carinii and mediates organism adherence to alveolar macrophages. J Clin Invest 1995, 95:2699.
135. Van Iwaarden JF, et al. Binding of surfactant protein A (SP-A) to herpes simplex virus type 1-infected cells is mediated by the carbohydrate moiety of SP-A. J Biol Chem 1992, 267:25039.
136. Gaynor CD, et al. Pulmonary surfactant protein A mediates enhanced phagocytosis of Mycobacterium tuberculosis by a direct interaction with human macrophages. J Immunol 1995, 155:5343.
137. Madan T, et al. Binding of pulmonary surfactant proteins A and D to Aspergillus fumigatus conidia enhances phagocytosis and killing by human neutrophils and alveolar macrophages. Infect Immun 1997, 65:3171.
138. Hickman-Davis JM, et al. Surfactant protein A mediates mycoplasmacidal activity of alveolar macrophages. Am J Physiol 1998, 274:L270.
139. LeVine AM, et al. Surfactant protein A-deficient mice are susceptible to group B streptococcal infection. J Immunol 1997, 158:4336.
140. LeVine AM, et al. Surfactant protein-A-deficient mice are susceptible to Pseudomonas aeruginosa infection. Am J Respir Cell Mol Biol 1998, 19:700.
141. LeVine AM, et al. Surfactant protein-A binds group B streptococcus enhancing phagocytosis and clearance from lungs of surfactant protein-A-deficient mice. Am J Respir Cell Mol Biol 1999, 20:279.
142. Sano H, et al. Pulmonary surfactant protein A modulates the cellular response to smooth and rough lipopolysaccharides by interaction with CD14. J Immunol 1999, 163:387.
143. Acton S, et al. The collagenous domains of macrophage scavenger receptors and complement component C1q mediate their similar, but not identical, binding specificities for polyanionic ligands. J Biol Chem 1993, 268:3530.
144. Madan T, et al. Lung surfactant proteins A and D can inhibit specific IgE binding to the allergens of Aspergillus fumigatus and block allergen-induced histamine release from human basophils. Clin Exp Immunol 1997, 110:241.
145. Wang JY, et al. Inhibitory effect of pulmonary surfactant proteins A and D on allergen-induced lymphocyte proliferation and histamine release in children with asthma. Am J Respir Crit Care Med 1998, 158:510.
146. Bevilacqua MP, Nelson RM Selectins. J Clin Invest 1993, 91:379.
147. Phillips ML, et al. Neutrophil adhesion in leukocyte adhesion deficiency syndrome type 2. J Clin Invest 1995, 96:2898.
148. Levy O, et al. Impaired innate immunity in the newborn: newborn neutrophils are deficient in bactericidal/permeability-increasing protein. Pediatrics 1999, 104:1327.
149. Steiner H, et al. Sequence and specificity of two antibacterial proteins involved in insect immunity. Nature 1981, 292:246.
150. Ganz T, Weiss J Antimicrobial peptides of phagocytes and epithelia. Semin Hematol 1997, 34:343.
151. Harwig SSL, et al. Neutrophil defensins: purification, characterization and antimicrobial testing. Methods Enzymol 1994, 236:160.
152. Goldman MJ, et al. Human β-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 1997, 88:553.
153. Selsted ME, Ouellette AJ Defensins in granules and non-phagocytic cells. Trends Cell Biol 1995, 5:114.
154. Dudley DJ, Wiedmeier S The ontogeny of the immune response: perinatal perspectives. Semin Perinatol 1991, 15:184-195. 184.
155. Haynes BF, et al. Early events in human T cell ontogeny: phenotypic characterization and immunohistologic localization of T cell precursors in early human fetal tissues. J Exp Med 1988, 168:1061.
156. Kingsley G, et al. Correlation of immunoregulatory function with cell phenotype in cord blood lymphocytes. Clin Exp Immunol 1988, 73:40.
157. Shyur SD, Hill HR Recent advances in the genetics of primary immunodeficiency syndromes. J Pediatr 1996, 129:8.
158. La Pine TR, Hill HR Immunomodifiers applicable to the prevention and management of infectious diseases in children. Advances in Pediatric Infectious Diseases 1994, Vol 9:37-58. Mosby-Year Book, St Louis. S.C. Arnoff (Ed.).
159. Stallmach T, et al. Cytokine production and visualized effects in the feto-maternal unit: quantitative and topographic data on cytokines during intrauterine disease. Lab Invest 1995, 73:384.
160. Carswell EA, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Nat Acad Sci USA 1975, 72:3666.
161. Haranaka K, et al. Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice. Int J Cancer 1984, 34:263.
162. Old LJ Tumor necrosis factor (TNF). Science 1985, 230:630.
163. Beutler B, et al. Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells. J Exp Med 1985, 161:984.
164. Kawakami M, Cerami A Studies of endotoxin-induced decrease in lipoprotein lipase activity. J Exp Med 1981, 154:631.
165. Beutler B, Cerami A Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature 1986, 320:584.
166. Movat HZ Tumor necrosis factor and interleukin-1: role in acute inflammation and microvascular injury. J Lab Clin Med 1987, 110:668.
167. Movat HZ, et al. Acute inflammation in gram-negative infection: endotoxin, interleukin-1, tumor necrosis factor, and neutrophils. Fed Proc 1987, 46:97.
168. Tracey KJ, et al. Cachectin: a hormone that triggers acute shock and chronic cachexia. J Infect Dis 1988, 157:413.
169. Salyer JL, et al. Mechanisms of tumor necrosis factor-alpha alteration of PMN adhesion and migration. Am J Pathol 1990, 136:831.
170. Koivuranta-Vaara P, et al. Bacterial-lipopolysaccharide-induced release of lactoferrin from human polymorphonuclear leukocytes: role of monocyte-derived tumor necrosis factor α. Infect Immun 1987, 55:2956.
171. Berkow RL, et al. Enhancement of neutrophil superoxide production by preincubation with recombinant human tumor necrosis factor. J Immunol 1987, 139:3783.
172. Tsujimoto M, et al. Tumor necrosis factor provokes superoxide anion generation from neutrophils. Biochem Biophys Res Commun 1986, 137:1094.
173. Fast DJ, et al. Toxic shock syndrome-associated staphylococcal and streptococcal pyogenic exotoxins are potent inducers of tumor necrosis factor production. Infect Immun 1989, 57:291.
174. Mancuso G, et al. Induction of tumor necrosis factor alpha by the group and type-specific polysaccharides form type III group B streptococci. Infect Immun 1994, 62:2748.
175. Vallejo JG, et al. Roles of the bacterial cell wall and capsule in induction of tumor necrosis factor alpha by type III group B streptococci. Infect Immun 1996, 64:5042.
176. Williams PA, et al. Production of tumor necrosis factor by human cells in vitro and in vivo, induced by group B streptococci. J Pediatr 1993, 123:292.
177. Okusawa S, et al. C5a stimulates secretion of tumor necrosis factor from human mononuclear cells in vitro. J Exp Med 1988, 168:443.
178. Schindler R, et al. Recombinant C5a stimulates transcription rather than translation of interleukin-1 (IL-1) and tumor necrosis factor: translational signal provided by lipopolysaccharide or IL-1 itself. Blood 1990, 76:1631.
179. Kremlev SG, Phelps DS Surfactant protein A stimulation of inflammatory cytokine and immunoglobulin production. Am J Physiol 1994, 267:L712.
180. Steele PM, et al. The effect of lactic acid on mononuclear cell secretion of proinflammatory cytokines in response to group B streptococci. J Infect Dis 1998, 177:1418.
181. Kwak DJ, et al. Intracellular and extracellular cytokine production by human mixed mononuclear cells in response to group B streptococci. Infect Immunity 2000, 68:320.
182. Teti G, et al. Cytokine appearance and effects of anti-tumor necrosis factor alpha antibodies in a neonatal rat model of group B streptococcal infection. Infect Immun 1993, 61:227.
183. - thymocytes are stimulated by interleukin-2 to proliferate in vitro in chemically defined medium. Thymus 1991, 18:15.
184. Bevilacqua MP, et al. Interleukin-1 acts on cultured human vascular endothelium to increase the adhesion of polymorphonuclear leukocytes, monocytes, and related cell lines. J Clin Invest 1985, 76:2003.
185. Cannon JG, et al. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 1990, 161:79.
186. Liechty KW, et al. Production of interleukin-6 by fetal and maternal cells in vivo during intraamniotic infection and in vitro after stimulation with interleukin-1. Pediatr Res 1991, 29:1.
187. +T helper cell 1 development in interleukin-6-deficient mice infected with Candida albicans. J Exp Med 1996, 183:1345.
188. Baggiolini M, et al. Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines. Adv Immunol 1994, 55:97.
189. Shimoya K, et al. Interleukin-8 in cord sera: a sensitive and specific marker for the detection of preterm chorioamnionitis. J Infect Dis 1992, 165:957.
190. Greenberger MJ, et al. Neutralization of macrophage inflammatory protein-2 attenuates, neutrophil recruitment and bacterial clearance in murine Klebsiella pneumonia. J Infect Dis 1996, 173:159.
191. Du X, Williams DA Interleukin-11: review of molecular, cell biology, and clinical use. Blood 1997, 89:3897.
192. - cell populations from cord blood versus adult bone marrow. Exp Hematol 1995, 23:1289.
193. - cells and synergizes with stem cell factor, interleukin-3, and granulocyte-macrophage colony-stimulating factor. Exp Hematol 1993, 21:1668.
194. Chang M, et al. Role of interleukin-11 (IL-11) during experimental group B streptococcal (GBS) sepsis in rats: prophylactic use of IL-11 improves survival and enhances platelet recovery (abstract). Blood 1994, 84:477.
195. Keith JC, et al. IL-11, a pleiotropic cytokine: exciting new effects of IL-11 on gastrointestinal mucosal biology. Stem Cells 1994, 12:79.
196. Du X, et al. The protective effects of interleukin-11 (IL-11) in a murine model of ischemic bowel necrosis. Am J Physiol 1997, 272:545.
197. Schindel D, et al. Interleukin-11 improves survival and reduces bacterial translocation and bone marrow suppression in burned mice. J Pediatr Surg 1997, 32:312.
198. Bank S, et al. Safety and activity evaluation of rhIL-11 in subjects with active Crohn's disease. Shock 1997, 7:520.
199. Trinchieri G Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995, 13:25.
200. Kobayashi M, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989, 170:827.
201. D'Andrea A, et al. Production of natural killer cell stimulatory factor (NKSF/IL-12) by peripheral blood mononuclear cells. J Exp Med 1992, 176:1387.
202. Aste-Amezaga M, et al. Molecular mechanisms of the induction of IL-12 and its inhibition by IL-10. J Immunol 1998, 160:5936.
203. Joyner JL, et al. Interleukin-12 increases IFNγ production by cord and adult blood mononuclear cells in response to group B streptococci. Pediatr Res 2000, 47:333A.
204. Snijders A, et al. Regulation of bioactive IL-12 production in lipopolysaccharide-stimulated human monocytes is determined by the expression of the p35 subunit. J Immunol 1996, 156:1207.
205. Cenci E, et al. IFNγ is required for IL-12 responsiveness in mice with Candida albicans infection. J Immunol 1998, 161:3543.
206. Presky DH, et al. A functional interleukin-12 receptor complex is composed of two beta-type cytokine receptor subunits. Proc Natl Acad Sci U S A 1996, 93:14002.
207. Mancuso G, et al. Role of interleukin-12 in experimental neonatal sepsis caused by group B streptococci. Infect Immun 1997, 65:373.
208. Ertel W, et al. Inhibition of the defense system stimulating interleukin-12 interferonγ pathway during critical illness. Blood 1997, 89:1612.
209. Borges WG, et al. Defective interleukin-12/interferonγ pathway in patients with hyperimmunoglobulinemia E syndrome. J Pediatr 2000, 136:176.
210. Dinarello CA IL-18: A Th1-inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol 1999, 103:11.
211. Takeda K, et al. Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity 1998, 8:383.
212. Gu Y, et al. Activation of interferonγ inducing factor mediated by interleukin-1β converting enzyme. Science 1997, 275:206.
213. Ghayur T, et al. Caspase-1 processes IFNγ-inducing factor and regulates LPS-induced IFNγ production. Nature 1997, 386:619.
214. Okamura H, et al. Cloning of a new cytokine that induces interferonγ. Nature 1995, 378:88.
215. Ushio S, et al. Cloning of the cDNA for human IFNγ-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein. J Immunol 1996, 156:4274.
216. Puren AJ, et al. Interleukin-18 (IFNγ-inducing factor) induces IL-1β and IL-8 via TNFα production from non-CD14+ human blood mononuclear cells. J Clin Invest 1998, 101:711.
217. La Pine TR, et al. Defective production of IL-18 and IL-12 by cord blood mononuclear cells influences the Th-1 IFNγ response to group B streptococci. Pediatr Res 2003, 54:276.
218. Hill HR, et al. Human recombinant interferon γ-enhances neonatal polymorphonuclear leukocyte activation and movement, and increases free intracellular calcium. J Exp Med 1991, 173:767.
219. Hill HR Modulation of host defenses with interferonγ in pediatrics. J Infect Dis 1993, 167:S23.
220. Dorman SE, Holland SM Interferon-gamma and interleukin-12 pathway defects and human disease. Cytokine Growth Factor Rev 2000, 11:321.
221. Holland SM Treatment of infections in the patient with Mendelian susceptibility to mycobacterial infection. Microbes Infect 2000, 2:1579.
222. Bryson YJ, et al. Deficiency of immune interferon production by leukocytes of normal newborns. Cell Immunol 1980, 55:191.
223. Wilson CB, et al. Decreased production of interferon-gamma by human neonatal cells: intrinsic and regulatory deficiencies. J Clin Invest 1986, 77:860.
224. Davis SD, et al. Job's syndrome: recurrent "cold" staphylococcal abscesses. Lancet 1966, 1:1013.
225. Del Prete G, et al. Defective in vitro production of γ-interferon and tumor necrosis factorα by circulating T cells from patients with the hyper-immunoglobulin E syndrome. J Clin Invest 1989, 84:1830.
226. Jeppson JD, et al. Use of recombinant human interferon gamma to enhance neutrophil chemotactic responses in Job syndrome of hyper-immunoglobulin E and recurrent infections. J Pediatr 1991, 118:383.
227. Petrak BA, et al. Recombinant human interferon gamma treatment of patients with Job's syndrome of hyperimmunoglobulin E and recurrent infections. Clin Res 1994, 42:1A.
228. International Chronic Granulomatous Disease Cooperative Study Group A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med 1991, 324:509.
229. Clark SC, Kamen R The human hematopoietic colony-stimulating factors. Science 1987, 236:1229.
230. Groopman JE, et al. Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with acquired immunodeficiency syndrome. Ann Intern Med 1984, 100:671.
231. Lau AS, et al. Biology and therapeutic uses of myeloid hematopoietic growth factors and interferons. Pediatr Infect Dis J 1996, 15:563.
232. Wolach B, et al. Effect of granulocyte and granulocyte macrophage colony stimulating factors (G-CSF and GM-CSF) on neonatal neutrophil functions. Pediatr Res 2000, 48:369.
233. Vadhan-Raj S, et al. Stimulation of myelopoiesis in patients with aplastic anemia by recombinant human granulocyte-macrophage colony-stimulating factor. N Engl J Med 1988, 319:1628.
234. Campbell JR, Edwards MS Cytokines enhance opsonophagocytosis of type III group B streptococcus. J Perinatol 2000, 20:225.
235. Roilides E, et al. Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils. J Infect Dis 1991, 163:579.
236. Zhang P, et al. Enhancement of peritoneal leukocyte function by granulocyte colony-stimulating factor in rats with abdominal sepsis. Crit Care Med 1998, 26:315.
237. Sullivan GW, et al. The effect of three human recombinant hepatopoietic growth factors (granulocyte-macrophage colony-stimulating factor, granulocyte colony-stimulating factor, and interleukin-3) on phagocyte oxidative activity. Blood 1993, 81:1863.
238. Pauksen K, et al. Serum levels of granulocyte colony-stimulating factor (G-CSF) in bacterial and viral infections, and in atypical pneumonia. Br J Haematol 1994, 88:256.
239. Kawakami M, et al. Levels of serum granulocyte colony-stimulating factor in patients with infections. Blood 1990, 76:1962.
240. Whiteside TL, Herberman RB Role of human natural killer cells in health and disease. Clin Diagn Lab Immunol 1994, 1:125.
241. Whiteside TL, Herberman RB The role of natural killer cells in human disease. Clin Immunol Immunopathol 1989, 53:1.
242. Seaman WE Natural killer cells. Clinical Immunology: Principles and Practice 1996, 282-289. Mosby, St. Louis. R.R. Rich (Ed.).
243. Bancroft GJ, et al. Natural immunity: a T-cell-independent pathway of macrophage activation, defined in the scid mouse. Immunol Rev 1991, 124:5.
244. Tripp CS, et al. Interleukin-12 and tumor necrosis factor alpha are costimulators of interferon gamma production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin-10 is a physiologic antagonist. Proc Natl Acad Sci U S A 1993, 90:3725.
245. Gazzinelli RT, et al. Interleukin-12 is required for the T- lymphocyte-independent induction of interferon gamma by an intracellular parasite and induces resistance in T cell-deficient hosts. Proc Natl Acad Sci U S A 1993, 90:6115.
246. Ching C, Lopez C Natural killing of herpes simplex virus type 1-infected target cells: normal human responses and influence of antiviral antibody. Infect Immun 1979, 26:49.
247. Kohl S, et al. Interferon induction of natural killer cytotoxicity in human neonates. J Pediatr 1981, 98:379.
248. van Furth R, et al. The immunologic development of the human fetus. J Exp Med 1965, 122:1173.
249. Cates KL, et al. The premature infant as a compromised host. Curr Prob Pediatr 1983, 13:1.
250. La Pine R, Hill HR Monoclonal antibodies. Semin Pediatr Infect Dis 2001, 12:64.
251. Burgio GR, et al. Ontogeny of secretory immunity: levels of secretory IgA and natural antibodies in saliva. Pediatr Res 1980, 14:1111.
252. Mellander L, et al. Secretory IgA antibody response against Escherichia coli antigens in infants in relation to exposure. J Pediatr 1985, 107:430.